Serum mucin antigens casa and msa in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients

Abstract

Background. The tumor markers CASA (cancer‐associated serum antigen) and MSA (mammary serum antigen) have previously been shown to be useful in the clinical management of ovarian and breast carcinoma, respectively, but have not been assessed in other types of cancer. These assays were compared with carcinoem‐bryonic antigen (CEA) and prostate‐specific antigen (PSA) in a blind trial using sera from the Mayo Clinic‐National Cancer Institute (NCI) Diagnostic Serum Bank. Methods. CASA and MSA were assessed retrospectively in a blind trial using 465 serum samples from the Mayo Clinic‐NCI Diagnostic Serum Bank representing malignant and benign disease of the breast, ovary, lung, pancreas, bladder,..